Users Online: 49 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 
 

 
Table of Contents
CASE REPORT
Year : 2011  |  Volume : 27  |  Issue : 4  |  Page : 531-533

Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency


1 Department of Critical Care Medicine, Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates
2 Department of Pharmacy, Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates

Date of Web Publication24-Oct-2011

Correspondence Address:
Said Abuhasna
Department of Critical Care Medicine, Tawam Hospital, P.O. Box 15258, Al Ain, Abu Dhabi
United Arab Emirates
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-9185.86601

Rights and Permissions
   Abstract 

We report the pharmacokinetics of vancomycin in an obese patient with renal insufficiency using pharmacokinetic equations, and comparing them with actual levels. A 47-year-old man with morbid obesity had a complicated hospital course with acute renal failure. Due to sputum growth of coagulase-negative Staphylococcus aureus, vancomycin 1500 mg intravenously twice daily was given empirically. Peak and trough plasma concentrations were drawn at steady state. Based on levels, true pharmacokinetic parameters for the patient were calculated using equations. This revealed that calculating individual pharmacokinetic parameters using equations may be a valid tool for dosing vancomycin in obese patients with renal insufficiency.

Keywords: Obese, renal insufficiency, vancomycin therapeutic drug monitoring


How to cite this article:
Abuhasna S, Al Jundi AH. Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency. J Anaesthesiol Clin Pharmacol 2011;27:531-3

How to cite this URL:
Abuhasna S, Al Jundi AH. Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency. J Anaesthesiol Clin Pharmacol [serial online] 2011 [cited 2017 Nov 20];27:531-3. Available from: http://www.joacp.org/text.asp?2011/27/4/531/86601


   Introduction Top


There are little or no well-controlled clinical trials until now that relate serum vancomycin concentrations to efficacy or toxicity, [1],[2],[3] but due to widespread interpatient variability in pharmacokinetic parameters, serum concentrations monitoring is needed in certain conditions, such as renal failure or changing renal function, to help avoid excessive peaks and troughs. From a pharmacodynamic perspective, vancomycin exhibits time-dependent killing of susceptible bacteria, so maintaining its concentration above the minimum inhibitory concentration (MIC) for the majority of the dosing interval is desirable.

Target peak concentrations are 30-40 mcg/mL, whereas target trough concentrations are 5-15 mcg/mL. [4],[5] It can even be higher (15-20 mcg/mL) in the treatment of certain serious conditions, such as meningitis, endocarditis, osteomylitis, and pneumonia, to ensure adequate penetration to the infected sites. [6] Steady-state conditions should be attained when obtaining Cpeak and Ctrough, the time to reach steady state plasma concentrations is 4-5 times the half-life.


   Case Report Top


A 47-year-old, 158 kg, 173 cm man with a past medical history of diabetes mellitus, hypertension, and obstructive sleep apnea on bi-level positive airway pressure (BiPAP) ventilation at home, was admitted to our intensive care unit following laparoscopic sleeve gastrectomy. The patient had a complicated hospital course due to an anastomotic leak. He underwent computed tomography-guided aspiration of abdominal collections, closing gastric fistula and transverse colon, and washing abdomen with repeated peritoneal lavage. The patient had developed peritonitis and sepsis, which was further complicated by the development of acute kidney injury.

His sputum cultures were positive for coagulase-negative Staphylococcus aureus (CNSA). The patient had no known allergies, and due to comorbidities and prevalence of methicillin-resistant S. aureus (MRSA) at our institution, vancomycin 1500 mg intravenously twice daily was started in addition to tigecycline and meropenem.

Since the patient experienced red-man syndrome with previous doses of vancomycin, the decision was to infuse the dose over 3 h (500 mg/h). Two peak and trough samples were drawn 6 days after starting vancomycin to ensure that steady state levels of vancomycin are attained. Levels revealed a peak and trough of 32.4 and 24.8 mg/L, respectively. Peak plasma concentration was drawn directly after finishing the infusion, so our calculations were based on that, while trough level was drawn just before giving the next dose.

Calculating true vancomycin pharmacokinetic parameters using equations [7]

Step 1: Calculating true elimination rate constant K:

K = (In Ct − In Cp)/(T − t − t')

where Cp is peak plasma concentration, Ct is trough plasma concentration, T is the dosing interval, t is the infusion time, t' is time after taking peak level.

Cp = 32.4 mg/L

Ct = 24.8 mg/L

K = (In 24.8 − In 32.4)/(12 − 3 − 0)

K = 0.0297/h

Step 2: Calculating true volume of distribution V:

Cp = (K 0 /3) (1 − e-Kt )/VK (1 − e-KT ).e-Kt' (K0 : dose of vancomycin infused)

Cp = 32.4 mg/L

Ct = 24.8 mg/L

32.4 = (1500/3)(1 − e (−0.0297Χ3) )/V(0.0297)(1 − e (−0.0297Χ12) )

Since t'= 0 then e (−0.0297Χ0) = 1Ζ

V = 148 L or 0.9 L/kg (patient's weight is 158 kg)

Step 3: Calculate recommended dosing interval (T) to achieve desired Cp of 25 mg and Ct of 10 mg/L

T = 1/−K[ In Ct - In Cp] + t + t'

T = [1/−0.0297 (In 10 − In 25)] + 3 + 0

T = 34 h rounded up to 36 h

Step 4: Calculating recommended dose (K0) to achieve desired levels

Cp = (K0) (1 − e-Kt )/VK (1 − e-KT ). e-Kt '

Since t'=0, then e (−0.0297Χ0) =1

Cp = (K0) (1 e-Kt )/VK (1 - e−KT ). e−Kt'

K0 = 830 mg in one hr = 2500 mg over 3 h

i. Dose should be 2500 mg q 36 h to achieve a peak concentration of 25 mg/L

ii. Expected trough concentration (Ct) using this dose and dosing interval

Ct = (Cp) (e−Kt" ) where t": time between Cp and Ct

Ct = (25) (e (−0.0297Χ33) )

Ct = 9.4 mg/L

Step 5: Check expected peak Cp and trough Ct:

i. The patient was then given 1500 mg q24, predicted peak as per calculations (dose was infused over 3 h and Cp obtained 1 h after finishing the infusion)

Cp = (K0/3)(1 e−Kt )/VK(1 − e−KT ). e−Kt '

Cp = (1500 mg/3)(1 e(−0.0297 Χ 3 ))/(148)(0.0297)(1 − e (−0.0297 Χ 24) .e (−0.0297 Χ 1) )

Cp = (42.6)(0.97)/(4.4 Χ 0.5)

Cp = 19 mg/L

ii. Actual peak level drawn 7 days after the new dose regimen was 22.7 mg/L; and this will correspond to a trough level of

Ct = (Cp) (e−Kt" ) where t" = 24 − 4 = 20 h

= (22.7) (e (−0.0297Χ20) )

= (22.7) (0.55)

= 12.5 mg/L


   Discussion Top


Vancomycin is eliminated almost entirely by glomerular filtration. [7] Therefore, conditions, such as renal impairment, will lead to reduced vancomycin clearance and increased plasma half-life. This patient had a normal baseline serum creatinine (87 micromole/L), but due to his sepsis and complicated hospital course, developed acute kidney injury as evident from his elevated serum creatinine (187 micromole/L). The reduced vancomycin clearance was evident from the discrepancy in population estimate of his vancomycin elimination rate constant (K) of 0.058/ before acute kidney injury [K= 0.00083/h (CrCl in mL/min) + 0.0044, where baseline CrCl is 65 mL/min] and true K of 0.0297−1 . This will also emphasize the importance of individualized dose adjustments based on true pharmacokinetic parameters. Until this time, most trials reported the use of total body weight (TBW), where higher total daily doses are given but at more frequent intervals to avoid high peak plasma concentrations. [8]

This case study is reported to identify if utilizing equations will better predict individualized pharmacokinetic parameters in obese patients with renal insufficiency as an alternative dosing method to mg/kg basis using TBW. At our institution, the MIC of S. aureus is reported to be 1 mcg/mL.

Murphy et al. [9] compared 7 different methods using TBW, ideal body weight (IBW), and adjusted body weight (ABW) for determining serum vancomycin concentration in 189 patients, 61% of whom weighed more than 1.2 times their IBW, but none of these methods used equations to optimize vancomycin monitoring. There is also paucity of data regarding the dosing of vancomycin in obese patients. In a multicenter pilot study, obese patients received inadequate empiric vancomycin. [10]

In our case, initial dose given for vancomycin was given empirically 1500 mg intravenously twice daily. Then, equations were used to calculate true pharmacokinetic parameters (K = 0.0297/1, V = 148 L) for this specific patient, calculating expected Cp and Ct based on these parameters, and then comparing them with measured values. Calculated value for vancomycin plasma concentration (Cp) based on true pharmacokinetic parameters was 19 mg/L, which was close to the reported value of 22.7 mg/L, even if based on dose that was given not calculated. Small discrepancy in the value may be due to fluctuating serum creatinine.

To conclude, calculating individual pharmacokinetic parameters using equations may be a valid tool for dosing vancomycin in obese patients with renal insufficiency.

 
   References Top

1.Duffull SB, Begg EJ. Vancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev 1994;13:103- 14.   Back to cited text no. 1
[PUBMED]    
2.Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.  Back to cited text no. 2
    
3.Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.  Back to cited text no. 3
    
4.Andres I, Lopez R, Pou L, Pinol F, Pascual C. Vancomycin monitoring: One or two serum levels? Ther Drug Monit 1997;19:614-9.   Back to cited text no. 4
    
5.Palmer-Toy DE. Therapeutic monitoring of vancomycin. Arch Pathol Lab Med 2000;124:322-3.   Back to cited text no. 5
[PUBMED]  [FULLTEXT]  
6.MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998;20:473-7.   Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.Dipiro JT, Spruill WJ, Blouin RA, Pruemer JM. Concepts in Clinical Pharmacokinetics. 4 th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2005. p. 173.  Back to cited text no. 7
    
8.Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21:575-80.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health-Syst Pharm 2006;63:2365-7.   Back to cited text no. 9
[PUBMED]  [FULLTEXT]  
10.Hall RG 2 nd , Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, et al. Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity. Am J Med 2008;121:515-8.  Back to cited text no. 10
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
    References

 Article Access Statistics
    Viewed2455    
    Printed123    
    Emailed0    
    PDF Downloaded556    
    Comments [Add]    

Recommend this journal